BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different
subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic
arthritis in order to select doses for further clinical trials.